GRI-0124 / GRI Bio - LARVOL DELTA

NKT cell activators potential SLE treatment, preclinical data show (Lupus News Today) - "GRI-0124, an oral small molecule being developed to activate natural killer T-cells, or NKT cells, and keep autoimmune attacks in check eased inflammation and prolonged survival in a mouse model of SLE, the company said...The company’s second small molecule candidate, GRI-0803, is similar in structure to GRI-0124 and has been found to be safe in preclinical studies. The way GRI-0803 is taken up and eliminated from the body supports the use of once-daily dosing in future studies...GRI-0124 and GRI-0803 appear to 'have the potential to target earlier in the inflammatory cascade to interrupt disease progression,' said Chaturvedi, who presented the data at the 14th International Congress on Autoimmunity...'We remain encouraged by GRI-0803’s potential and are working in earnest to validate bioanalytical methods, complete cGMP manufacturing, and complete toxicology studies in order to file our IND for GRI-0803 in the second half of 2024'..."

IND • Preclinical • Systemic Lupus Erythematosus

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE) (GlobeNewswire) - "Once-weekly GRI-0124: Inhibited pro-inflammatory cytokines and signaling pathways in NZBWF1 mice; Decreased pDC accumulation and MHC class II expression;...Reduced renal cellular infiltration and fibrosis....GRI-0803 has demonstrated: Chemistry backbone based on type 2 GRI-0124; <400g/mol; Favorable solubility profile; Excellent bioavailability; PK profile supporting q.d. administration orally....Data presented at the 14th International Congress on Autoimmunity."

Preclinical • Systemic Lupus Erythematosus